Roche Venture Fund Portfolio

Current Investment Portfolio

Exits via M&A
M&A
  • Afferent (acquired by Merck)

  • Alios (acquired by Johnson+Johnson)

  • Ambit (acquired by Daiichi Sankyo)

  • Ambrx (acquired by Wuxi)

  • Artus (acquired by Qiagen)

  • Avexis (acquired by Novartis)

  • BioFire (acquired by bioMérieux)

  • BioXell (acquired by Cosmo)

  • Care Innovations (acquired by PRA Health Sciences)

  • CGI (acquired by Gilead)

  • DVS (acquired by Fluidigm)

  • Envoy (acquired by Takeda)

  • Flatiron (acquired by Roche)

  • Foundation Medicine (acquired by Roche)

  • HistoRx (acquired by Genoptix)

  • Leukosite (acquired by Millennium)

  • LTI (acquired by Bial)

  • Memory (acquired by Roche)

  • Miikana (acquired by EntreMed)

  • MySugr (acquired by Roche)

  • Pandion (acquired by Merck)

  • Sequana (acquired by Celera)

  • Stratos Genomics (acquired by Roche)

  • Syrrx (acquired by Takeda)

  • Tripath (acquired by Becton Dickinson)

  • Viewics (acquired by Roche)

  • Zikanii (acquired by Eloxx)

Historic Investment Portfolio

Exits via IPO
IPOs
  • Addex

  • Aileron

  • Anadys

  • Black Diamond Therapeutics

  • C4 Therapeutics

  • Caliper

  • Complete Genomics

  • Conatus

  • Curetis

  • CV Therapeutics

  • CytomX

  • deCode

  • Fibrogen, Inc

  • Halozyme Therapeutics

  • Horizon Discovery

  • Miragen

  • Pharmasset

  • Protein Design Labs, Inc

  • Senseonics

  • Taimed

  • TiGenix

  • Xenon

Historic Investment Portfolio